Skip to Content
Merck
CN

L6668

Lercanidipine hydrochloride

≥98% (HPLC), powder, dihydropyridine calcium-channel blocker

Synonym(s):

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester 3,5-pyridinedicarboxylic acid hydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C36H41N3O6 · HCl
CAS Number:
132866-11-6
Molecular Weight:
648.19
UNSPSC Code:
12352200
PubChem Substance ID:
24724527
NACRES:
NA.77
MDL number:
MFCD07773089

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Lercanidipine hydrochloride, ≥98% (HPLC)

SMILES string

O=C(OC)C1=C(C)NC(C)=C(C(OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)=O)C1C4=CC([N+]([O-])=O)=CC=C4.Cl

InChI

1S/C36H41N3O6.ClH/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27;/h7-19,22,30,33,37H,20-21,23H2,1-6H3;1H

InChI key

WMFYOYKPJLRMJI-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated
protect from light

color

yellow

originator

Forest Labs

storage temp.

2-8°C

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Lercanidipine hydrochloride is a L-type (Cav1.2b) vascular channel antagonist; L-type (Cav1.2a) cardiac channel agonist voltage-dependent and highly lipophylic compound, which exhibits a slower onset and longer duration of action than other calcium channel antagonists; an antihypertensive agent in patients with mild-to-moderate hypertension; more vasoselective than lacidipine and amlodipine.
Lercanidipine hydrochloride is a L-type (Cav1.2b) vascular channel antagonist; L-type (Cav1.2a) cardiac channel agonist.

Features and Benefits

This compound was developed by Forest Labs. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000486719
0000486719
0000503225
0000503225
0000408053

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

George Hadjipavlou et al.
Scandinavian journal of trauma, resuscitation and emergency medicine, 19(1), 8-8 (2011-01-22)
This case report describes the first reported overdose of the dihydropyridine calcium channel blocker (CCB) lercanidipine. A 49 yr old male presented to the Emergency Department 3 hrs after the ingestion of 560 mg of lercanidipine. In the department he
Arrigo F G Cicero et al.
Clinical and experimental hypertension (New York, N.Y. : 1993), 34(2), 113-117 (2011-10-05)
The aim of this study is to assess the blood pressure (BP) and metabolic effects of lercanidipine when combined with other classes of first-line antihypertensive drugs in day-to-day clinical practice. For this study, we consecutively enrolled 162 patients with uncomplicated
Nitin Parmar et al.
Colloids and surfaces. B, Biointerfaces, 86(2), 327-338 (2011-05-10)
The present study deals with the development and characterization of self-nanoemulsifying drug delivery system (SNEDDS) to improve the oral bioavailability of poorly soluble third generation calcium channel blocker lercanidipine (LER). Solubility of the LER was estimated in various oils, cosurfactants
Mehmet Gumustas et al.
Talanta, 82(4), 1528-1537 (2010-08-31)
In this study, pK(a) values were determined using the dependence of the retention factor on the pH of the mobile phase for three ionizable substances, namely, enalapril, lercanidipine and ramipril (IS). The effect of the mobile phase composition on the
Jürgen Scholze et al.
Expert opinion on pharmacotherapy, 12(18), 2771-2779 (2011-10-18)
A fixed-dose combination (FDC) of enalapril and lercanidipine has been shown to be effective and safe in reducing blood pressure in randomized clinical trials. This study aims to determine effectiveness and safety in daily practice. This was a prospective, open-label
View All Related Papers

Articles

Calcium Channels

We offers many products related to calcium channels for your research needs.

钙通道

我们提供多种与钙通道相关的产品以满足您的各类研究需求。

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service